China Chinese Patent Medicine Industry Report, 2012-2015
  • Apr.2013
  • Hard Copy
  • USD $2,200
  • Pages:88
  • Single User License
    (PDF Unprintable)       
  • USD $2,100
  • Code: WLQ001
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,300
  • Hard Copy + Single User License
  • USD $2,400
In recent years, China’s Chinese patent medicine industry has been running in good condition, with the revenue increasing from RMB 142 billion in 2008 to RMB 360 billion in 2012 at a CAGR of 26.2%. Over the same period, the total profit maintained a CAGR of 26.6%, and the gross margin remained higher than the average level of the overall pharmaceutical industry.

In succession to the Opinions on Promoting the Development of Traditional Chinese Medicine Services and Trade, the Twelfth Five-Year Plan on the Development of Traditional Chinese Medicine and other favorable policies, the new National Essential Drugs List published in March 2013 increased the number of Chinese patent medicine from 102 in 2009 to 203, and the proportion in total quantity from 33% to 39%. As a result, China’s Chinese patent medicine market demand is expected to grow rapidly in the next five years.

Revenue and YoY Growth Rate of China’s Chinese Patent Medicine Industry, 2008-2012

Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases, tumor diseases, respiratory system diseases, musculoskeletal diseases and digestive system diseases are top five categories of Chinese patent medicine for hospitals in China. The Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases occupies the largest market share, which remained at around 37% in 2006-2012. Outstanding enterprises producing Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases include Shandong Buchang Pharma (products include Guanxin Shutong Capsule and Naoxinshu Oral Solution), Tianjin Tasly Group (products include Compound Danshen Dripping Pills and Yangxue Qingnao Granule), Jinling Pharmaceutical (products include Mailuoning Injection and Mailuoning Oral Solution), Shijiazhuang Yiling Pharmaceutical (products include Tongxinluo Capsule and Shensong Yangxin Capsule), etc.

As China's Chinese patent medicine is gaining international recognition, coupled with the incentive from high profit (the operating margin is generally above 70%) and the development bottleneck of the chemical pharmaceutical industry, foreign enterprises and institutions such as Novartis, Merck, Johnson & Johnson, GSK have set foot in the Chinese patent medicine market through joint ventures and wholly-owned subsidiaries. For example, in early 2013, GSK announced to carry out drug development trying to use traditional Chinese medicinal ingredients in China.

China Chinese Patent Medicine Industry Report, 2012-2015 of ResearchInChina mainly includes the following contents:

20120114.gif Industrial policies, development status, regional market, import and export, development trend of China’s Chinese patent medicine industry;
20120114.gif Development status of the raw material market of China’s Chinese patent medicine industry as well as the development status and import & export of China’s plant extracts;
20120114.gif China’s Chinese patent medicine market segments, including Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases, tumor diseases, respiratory system diseases, etc.;
20120114.gif Operation, revenue structure, gross margin and profit forecast of China's 10 major Chinese patent medicine production enterprises.

1. Overview of Chinese Patent Medicine
1.1 Definition and Features
1.2 Classification
1.2.1 Classification by Dosage Form
1.2.2 Classification by Pharmacology 
1.2.3 Industry Chain

2. Operating Environment for Chinese Patent Medicine Industry
2.1 Policies 
2.1.1 Domestic Policies 
2.1.2 Foreign Policies 
2.2 Consumption Trend
2.3 Industry Trend

3. Market of Chinese Patent Medicine Industry 
3.1 Development Status 
3.2 Supply and Demand 
3.2.1 Supply 
3.2.2 Demand 
3.3 Regional Market 
3.4 Import and Export 
3.4.1 Export 
3.4.2 Import 
3.5 Demand Trend 
3.5.1 Overview of Pharmaceutical Demand 
3.5.2 Population Aging Promotes Market Demand of Pharmaceutical Industry 
3.5.3 Urbanization Increases Healthcare Market Demand 
3.5.4 Disease Trend
3.6 Traditional Chinese Medicinal Materials 
3.6.1 Resources 
3.6.2 Price Trend 
3.7 Plant Extract 
3.7.1 Development Status
3.7.2 Import and Export 

4. Chinese Patent Medicine Market Segments in China
4.1 Overview 
4.2 Chinese Patent Medicine for Cardiovascular and Cerebrovascular Diseases 
4.3 Chinese Patent Medicine for Tumor Diseases 
4.4 Chinese Patent Medicine for Respiratory System Diseases 
4.5 Chinese Patent Medicine for Musculoskeletal Diseases

5. Key Producers of Chinese Patent Medicine
5.1 Tianjin Tasly Pharmaceutical Co., Ltd. 
5.1.1 Profile 
5.1.2 Operation 
5.1.3 Revenue Structure 
5.1.4 Gross Margin 
5.1.5 Development Prospect 
5.2 Guizhou Yibai Pharmaceutical Co., Ltd. 
5.2.1 Profile 
5.2.2 Operation 
5.2.3 Revenue Structure 
5.2.4 Gross Margin 
5.2.5 Development Prospect 
5.3 Yunnan Baiyao Group Co., Ltd. 
5.3.1 Profile 
5.3.2 Operation 
5.3.3 Revenue Structure 
5.3.4 Gross Margin 
5.3.5 Development Prospect 
5.4 Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. 
5.4.1 Profile 
5.4.2 Operation 
5.4.3 Revenue Structure 
5.4.4 Gross Margin 
5.4.5 Development Prospect 
5.5 Shandong Dong-E E-Jiao Co., Ltd. 
5.5.1 Profile 
5.5.2 Operation 
5.5.3 Revenue Structure 
5.5.4 Gross Margin 
5.5.5 Development Prospect 
5.6 China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu) 
5.6.1 Profile 
5.6.2 Operation 
5.6.3 Revenue Structure 
5.6.4 Gross Margin 
5.6.5 Development Prospect 
5.7 Shanghai Kaibao Pharmaceutical Co., Ltd. 
5.7.1 Profile 
5.7.2 Operation 
5.7.3 Revenue Structure 
5.7.4 Gross Margin 
5.7.5 Development Prospect 
5.8 Kangmei Pharmaceutical Co., Ltd. 
5.8.1 Profile 
5.8.2 Operation 
5.8.3 Revenue Structure 
5.8.4 Gross Margin 
5.8.5 Development Prospect 
5.9 Tibet Rhodiola Pharmaceutical Holding Co., Ltd. 
5.9.1 Profile 
5.9.2 Operation 
5.9.3 Revenue Structure 
5.9.4 Gross Margin 
5.9.5 Development Prospect 
5.10 Beijing Tongrentang Co., Ltd. (TRT) 
5.10.1 Profile 
5.10.2 Operation 
5.10.3 Revenue Structure 
5.10.4 Gross Margin 
5.10.5 Development Prospect 

Advantages and Disadvantages of Chinese Patent Medicine 
Classification of Chinese Patent Medicine by Dosage Form
Classification of Chinese Patent Medicine by Pharmacology 
Chinese Patent Medicine Industry Chain
Chinese Patent Medicine-related National Policies 
Number of Chinese Patent Medicine Enterprises in China, 2008-2012
Revenue and YoY Growth Rate of Chinese Patent Medicine Industry in China, 2008-2012 
Total Profit and YoY Growth Rate of Chinese Patent Medicine Industry in China, 2008-2012 
Gross Margin of Chinese Patent Medicine Enterprises in China, 2011-2012 
Output and YoY Growth Rate of Chinese Patent Medicine in China, 2008-2012
Output of Top 10 Chinese Patent Medicine Producing Regions in China, 2012
Sales of Top 10 Chinese Patent Medicine Sales Regions in China, 2011
Sales Structure of Top 10 Chinese Patent Medicine Sales Regions in China, 2011
Top 10 Chinese Provinces/Municipalities by Number of Above-scale Chinese Patent Medicine Enterprises, 2012
Top 10 Chinese Provinces/Municipalities by Sales of Chinese Patent Medicine Enterprises, 2012
Top 10 Chinese Provinces/Municipalities by Total Profit of Chinese Patent Medicine Enterprises, 2012
Chinese Provinces/Municipalities with Gross Margin of Chinese Patent Medicine Enterprises Above 40%, 2012
Number of Enterprises, Sales and Total Profit of China’s Chinese Patent Medicine Market by Region, 2012
China’s Chinese Patent Medicine Export Volume and YoY Growth Rate, 2008-2012
China’s Chinese Patent Medicine Export Value and YoY Growth Rate, 2008-2012
China’s Chinese Patent Medicine Export Destinations, Export Value and Products, 2012
China’s Chinese Patent Medicine Export Destination Structure by Export Value, 2012
China’s Chinese Patent Medicine Export Products, Export Volume and Export Destinations, 2012
China’s Top 10 Chinese Patent Medicine Export Enterprises, 2011
China’s Top 5 Chinese Patent Medicine Export Enterprises, 2012 
China’s Chinese Patent Medicine Import Value and YoY Growth Rate, 2008-2012 
Revenue and Share in Pharmaceutical Industry of China’s Chinese Patent Medicine Industry, 2008-2012
China’s Population Aged 65 and Above, 2002-2012
Per Capita Healthcare Expenditure of China’s Urban and Rural Residents, 2001-2011
China’s Number of Hospitals and CAGR, 2001-2011
China’s Panax Notoginseng Price, 2008-2012
Trend Chart of Traditional Chinese Medicinal Material Comprehensive 200 Index, 2007-2012
Price Index of Traditional Chinese Medicinal Materials in Chengdu, China, 2010-2012
Major Traditional Chinese Medicinal Material GAP Enterprises in China, 2012
China’s Plant Extract Import and Export Value, 2008-2012
China’s Plant Extract Export Destination Structure by Export Value, 2012
Share of Chinese Patent Medicine in the Medicine Sold to Hospitals in China by Disease, 2011
Four Major Types of Chinese Patent Medicine for Cardiovascular and Cerebrovascular Diseases
Share of Chinese Patent Medicine for Cardiovascular and Cerebrovascular Diseases in the Chinese Patent Medicine Sold to Hospitals in China, 2007-2011
Excellent Brands of Chinese Patent Medicine for Cardiovascular and Cerebrovascular Diseases, 2012
Share of Chinese Patent Medicine for Tumor Diseases in the Chinese Patent Medicine Sold to Hospitals in China, 2007-2011
Top 10 Excellent Brands of Chinese Patent Medicine for Tumor Diseases in China, 2012
Share of Chinese Patent Medicine for Respiratory System Diseases in the Chinese Patent Medicine Sold to Hospitals in China, 2007-2011
Chinese Patent Medicine for Respiratory System Diseases in Sample Hospital by Type, 2009
Excellent Brands of Chinese Patent Medicine for Respiratory System Diseases, 2012
Share of Chinese Patent Medicine for Musculoskeletal Diseases in the Chinese Patent Medicine Sold to Hospitals in China, 2007-2011
China’s Top 10 Excellent Brands of Traditional Chinese Medicine for Musculoskeletal Diseases, 2012
Revenue and YoY Growth Rate of Tasly, 2008-2012 
Net Income and YoY Growth Rate of Tasly, 2008-2012 
Revenue of Tasly by Sector, 2008-2012 
Revenue of Tasly by Region, 2008-2012 
Gross Margin of Tasly by Sector, 2008-2012 
Gross Margin of Tasly by Region, 2009-2012 
Revenue and Net Income of Tasly, 2011-2015 
Revenue and YoY Growth Rate of Yibai Pharmaceutical, 2008-2012
Net Income and YoY Growth Rate of Yibai Pharmaceutical, 2008-2012
Revenue of Yibai Pharmaceutical by Sector, 2009-2012 
Revenue of Yibai Pharmaceutical by Product, 2008-2012 
Revenue of Yibai Pharmaceutical by Region, 2008-2012 
Gross Margin of Yibai Pharmaceutical by Sector, 2009-2012 
Gross Margin of Yibai Pharmaceutical by Product, 2008-2012 
Gross Margin of Yibai Pharmaceutical by Region, 2008-2012 
Revenue and Net Income of Yibai Pharmaceutical, 2011-2015 
Revenue and YoY Growth Rate of Yunnan Baiyao, 2008-2012 
Net Income and YoY Growth Rate of Yunnan Baiyao, 2008-2012 
Revenue of Yunnan Baiyao by Sector, 2008-2012 
Revenue of Yunnan Baiyao by Product, 2009-2012 
Revenue of Yunnan Baiyao by Region, 2008-2012
Gross Margin of Yunnan Baiyao by Sector, 2008-2012 
Gross Margin of Yunnan Baiyao by Product, 2009-2012 
Gross Margin of Yunnan Baiyao by Region, 2008-2012
Revenue and Net Income of Yunnan Baiyao, 2011-2015 
Revenue and YoY Growth Rate of Pientzehuang, 2008-2012
Net Income and YoY Growth Rate of Pientzehuang, 2008-2012 
Revenue of Pientzehuang by Sector, 2008-2012 
Revenue of Pientzehuang by Region, 2008-2012 
Gross Margin of Pientzehuang by Sector, 2008-2012 
Gross Margin of Pientzehuang by Product, 2008-2012 
Gross Margin of Pientzehuang by Region, 2008-2012 
Revenue and Net Income of Pientzehuang, 2011-2015 
Revenue and YoY Growth Rate of Dong-E E-Jiao, 2008-2012 
Net Income and YoY Growth Rate of Dong-E E-Jiao, 2008-2012 
Revenue of Dong-E E-Jiao by Product, 2008-2012 
Revenue of Dong-E E-Jiao by Region, 2008-2012 
Gross Margin of Dong-E E-Jiao by Product, 2008-2012 
Gross Margin of Dong-E E-Jiao by Region, 2009-2012 
Revenue and Net Income of Dong-E E-Jiao, 2011-2015 
Revenue and YoY Growth Rate of CR Sanjiu, 2008-2012 
Net Income and YoY Growth Rate of CR Sanjiu, 2008-2012 
Revenue of CR Sanjiu by Sector, 2008-2012 
Revenue of CR Sanjiu by Region, 2008-2012 
Gross Margin of CR Sanjiu by Sector, 2008-2012 
Revenue and Net Income of CR Sanjiu, 2011-2015
Revenue and YoY Growth Rate of Shanghai Kaibao, 2008-2012 
Net Income and YoY Growth Rate of Shanghai Kaibao, 2008-2012 
Revenue of Shanghai Kaibao by Product, 2008-2012 
Revenue of Shanghai Kaibao by Region, 2008-2012 
Gross Margin of Shanghai Kaibao by Product, 2008-2012 
Revenue and Net Income of Shanghai Kaibao, 2011-2015 
Revenue and YoY Growth Rate of Kangmei Pharmaceutical, 2008-2012 
Net Income and YoY Growth Rate of Kangmei Pharmaceutical, 2008-2012 
Revenue of Kangmei Pharmaceutical by Region, 2008-2012 
Gross Margin of Kangmei Pharmaceutical by Region, 2008-2012 
Revenue and Net Income of Kangmei Pharmaceutical, 2011-2015 
Revenue and YoY Growth Rate of Tibet Rhodiola Pharmaceutical, 2008-2012 
Net Income and YoY Growth Rate of Tibet Rhodiola Pharmaceutical, 2008-2012 
Revenue of Tibet Rhodiola Pharmaceutical by Product, 2008-2012 
Revenue of Tibet Rhodiola Pharmaceutical by Region, 2008-2012 
Gross Margin of Tibet Rhodiola Pharmaceutical by Sector, 2008-2012 
Gross Margin of Tibet Rhodiola Pharmaceutical by Product, 2008-2012 
Gross Margin of Tibet Rhodiola Pharmaceutical by Region, 2008-2012 
Revenue and Net Income of Tibet Rhodiola Pharmaceutical, 2011-2015 
Revenue and YoY Growth Rate of Tongrentang, 2008-2012 
Net Income and YoY Growth Rate of Tongrentang, 2008-2012 
Revenue of Tongrentang by Region, 2008-2012 
Gross Margin of Tongrentang by Region, 2009-2012 
Revenue and Net Income of Tongrentang, 2011-2015 

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号